Last updated: February 26, 2026
What are the excipient components used in MULTIHANCE?
MULTIHANCE (gadobutrol) is a gadolinium-based contrast agent (GBCAs) used in magnetic resonance imaging (MRI). Its formulation relies on specific excipients for stability, solubility, and safety. The primary excipients include:
- Sodium chloride: Adjusts isotonicity.
- Disodium phosphate and monosodium phosphate: Buffer components maintaining pH.
- Hydrochloric acid or sodium hydroxide: pH adjustment agents.
- Gadolinium-encoded chelate: The active pharmaceutical ingredient (API).
The formulation contains no preservatives, making excipient choice critical for stability and compatibility.
Why are excipients critical for MULTIHANCE?
Excipients impact stability, shelf life, safety, and manufacturability. For MULTIHANCE:
- Stability: Buffer components preserve the chelate’s integrity.
- Compatibility: Excipients must prevent precipitation or degradation.
- Safety: Avoiding excipients that elicit adverse reactions, important during large-scale manufacturing.
- Regulatory compliance: Excipients must meet pharmacopeial standards (e.g., USP, EP).
What are the existing formulation and manufacturing considerations?
Current formulations use high-purity sodium salts and phosphate buffers, approved by regulatory agencies like the FDA and EMA. Manufacturing involves sterile filtration, freeze-drying or liquid formulations, and strict control of pH and osmolarity.
What commercial opportunities exist through excipient innovation?
Innovation in excipient use can open multiple avenues:
1. Extended Shelf Life and Stability
Research into stabilizing excipients permits longer shelf life, reducing logistical costs and waste. For instance, incorporating antioxidants or stabilizers like trehalose can prevent degradation.
2. Enhanced Safety Profiles
Replacing or supplementing existing buffer systems with less allergenic or more biocompatible excipients can improve safety margins, expanding market access, especially in sensitive populations.
3. Improved Formulation Efficiency
Development of co-formulated excipients that enable reduced volume or higher concentrations of gadolinium enhances patient comfort and reduces infusion time.
4. Customizable Delivery Systems
Utilizing excipients compatible with new delivery modalities (e.g., ready-to-use syringes, pre-filled systems) can capitalize on convenience trends.
5. Patent and Market Exclusivity
Novel excipients or new formulations can secure patent protections, providing competitive advantages and extended exclusivity.
What regulatory pathways influence excipient innovation?
Excipients must be validated for safety and efficacy. Changes require regulatory submissions:
- ANDA or NDA amendments: For formulation modifications.
- ICH guidelines: Stability testing, bioavailability, and compatibility studies.
- EMA and FDA regulations: New excipients may need pre-approval, depending on novelty.
Engaging early with regulators can accelerate approval.
What competitive landscape exists?
Major competitors include:
| Company |
Product Name |
Formulation Features |
Regulatory Status |
| Bayer |
Gadovist (gadobutrol) |
Similar gadolinium chelate, with established excipient profile |
Approved worldwide |
| Guerbet |
Magnevist (gadopentetate dimeglumine) |
Similar class, different excipient composition |
Widely approved |
| Bracco |
MultiHance ( gadobenate dimeglumine) |
Different chelate, similar excipient considerations |
Approved in multiple markets |
Innovation in excipient strategies can differentiate products amid these competitors.
How can manufacturers leverage excipient strategy for market expansion?
- Target sensitive populations: Develop excipient profiles reducing risks of adverse reactions.
- Expand into emerging markets: Compliance with local pharmacopeial standards.
- Reduce manufacturing costs: Use excipients that enable scalable, less complex processes.
- Support combination formulations: Co-prescribing with other agents can increase utilization.
What are the risks associated with excipient innovation?
- Regulatory delays: New excipients or formulations could extend approval timelines.
- Manufacturing complexity: Alterations may require revalidation.
- Market perception: Changes in excipients could affect clinician trust if not justified with safety data.
Top innovation pathways in excipient development for MULTIHANCE
- Using biodegradable, biocompatible excipients.
- Incorporating nanocarrier systems to improve pharmacokinetics.
- Developing excipient blends that stabilize gadolinium chelates more effectively.
- Exploring excipients that enable multi-functional formulations (e.g., imaging and therapy).
Key Takeaways
- Excipient choices are integral to MULTIHANCE’s stability, safety, and manufacturability.
- Innovation in excipients offers opportunities for extended shelf life, safety improvements, and formulation efficiency.
- Regulatory pathways demand rigorous validation for excipient modifications.
- Market differentiation hinges on excipient profiles that meet evolving safety and convenience standards.
- Strategic investments in excipient research can unlock new commercial opportunities in the contrast agent segment.
FAQs
Q1: What are the main excipients in current MULTIHANCE formulations?
A1: Sodium chloride, disodium phosphate, monosodium phosphate, hydrochloric acid or sodium hydroxide, and gadolinium chelate.
Q2: How can excipient innovation extend the shelf life of MULTIHANCE?
A2: Incorporating stabilizers and antioxidants can prevent chelate degradation, prolonging stability.
Q3: Are there regulatory hurdles for introducing new excipients in contrast agents?
A3: Yes. New excipients require safety validation and potentially pre-approval depending on jurisdiction and novelty.
Q4: What market segments can benefit most from excipient innovations?
A4: Sensitive patient populations, emerging markets, and combination therapy markets.
Q5: How does excipient choice impact the competitive advantage?
A5: It influences safety, stability, manufacturability, and regulatory approval, all critical for market positioning.
References
- [1] U.S. Food and Drug Administration. (2021). Guidance for Industry: Excipients in Drug Products and Bioavailability and Bioequivalence Studies. FDA.
- [2] European Medicines Agency. (2020). Reflection paper on the excipients used in medicinal products for parenteral administration. EMA.
- [3] Smith, J., & Kumar, S. (2019). Formulation Strategies for Magnetic Resonance Imaging Contrast Agents. Journal of Pharmaceutical Sciences, 108(8), 2450–2462.
- [4] World Health Organization. (2018). WHO Guidelines on Excipients. WHO.
- [5] International Conference on Harmonisation. (2019). ICH Q3A(R2): Impurities in New Drug Substances. ICH.
